National Multiple Sclerosis Society

Accelerated Cure Project for Multiple Sclerosis has launched iConquerMS

Wednesday, February 4, 2015

The Accelerated Cure Project for Multiple Sclerosis has launched iConquerMS, a nationwide initiative by and for individuals living with multiple sclerosis who recognize the power of their health data and insights and want to harness that power to fuel research. The initiative’s portal,, enables all people living with MS to play an active role in research, empowering them to securely submit their health data, propose topics of research that are most important to them, influence the research that is carried out by the initiative and become informed about the research process and specific studies.

[Read More]

Glialogix, National Multiple Sclerosis Society collaborate

Thursday, October 2, 2014

Glialogix, a San Francisco Bay Area-based emerging biopharma company, has entered into a sponsored research agreement with Fast Forward, a nonprofit organization established by the New York-based National Multiple Sclerosis (MS) Society to accelerate the development of treatments for MS. Fast Forward will provide funding for preclinical studies of GLX1112, a first-in-class neuroprotective therapy designed to slow the accumulation of disability in progressive MS.

[Read More]

National MS Society, GE Healthcare partner

Wednesday, October 2, 2013

The National Multiple Sclerosis Society is collaborating with GE Healthcare through Fast Forward, a nonprofit subsidiary of the National Multiple Sclerosis Society, to co-fund a clinical study with the GE investigational PET tracer, GE180, in patients with multiple sclerosis (MS). The clinical study, which will be enrolling patients in the U.K., is aimed to aid in physicians’ understanding of whether imaging neuroinflammation in MS patients before and after treatment with natalizumab (Tysabri) can help identify which patients may respond to treatment.

[Read More]

Linegen, Fast Forward collaborate to develop gene and biomarker assays for MS

Friday, December 16, 2011

Lineagen and Fast Forward, a nonprofit subsidiary of the National Multiple Sclerosis Society, have formed an alliance to fund the clinical development and validation of a blood-based assay for multiple sclerosis (MS). The goal of the program is to develop a test that can aid clinicians in diagnosing MS, distinguishing it from other neurological disorders, and providing the prognostic information needed to help guide treatment decisions and response to therapies.

[Read More]